Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges
Open Access
Abstract
Prostate cancer is the most frequent malignant tumor in men, and, despite the great improvements in survival in patients with localized cancer, the prognosis for metastatic disease remains poor. Novel molecular targeted therapies, which block specific molecules or signaling pathways in tumor cells or in their microenvironment, have shown encouraging results in metastatic castration-resistant prostate cancer. Among these therapeutic approaches, prostate-specific membrane antigen-targeted radionuclide therapies and DNA repair inhibitors represent the most promising ones, with some therapeutic protocols already approved by the FDA, whereas therapies targeting tumor neovascularization and immune checkpoint inhibitors have not yet demonstrated clear clinical benefits. In this review, the most relevant studies and clinical trials on this topic are illustrated and discussed, together with future research directions and challenges.Keywords
Funding Information
- AIRC (Associazione Italiana Per La Ricerca Sul Cancro) (23264)
- MUR (Ministero dell’Università e della Ricerca) (23264)
- Programma Operativo Nazionale Ricerca e Innovazione 2014–2020 (PON R&I) (23264)
This publication has 123 references indexed in Scilit:
- Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer CellsPLOS ONE, 2013
- PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer CellsPLOS ONE, 2013
- Causes, consequences, and reversal of immune system agingJournal of Clinical Investigation, 2013
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401Journal of Clinical Oncology, 2012
- GSTP1 DNA Methylation and Expression Status Is Indicative of 5-aza-2′-Deoxycytidine Efficacy in Human Prostate Cancer CellsPLOS ONE, 2011
- Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate CancerMolecular Cancer Therapeutics, 2011
- Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing RadiationMolecular Cancer Therapeutics, 2011
- A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancerOncogene, 2005
- The biology of VEGF and its receptorsNature Medicine, 2003
- DNA double-strand break repairCurrent Biology, 1999